Dr. Philippe Chemla is Chief Business Officer at GeneCentric. Prior to joining GeneCentric, Dr. Chemla served as President of Diabetic Health Inc., CEO and Director at Clinical Sensors, which he negotiated the acquisition, Chief Business Officer for the David H. Murdock Research Institute, which he restructured as a commercial CRO, Vice President of Business Development at Metabolon where he led strategic engagements, and Director of Commercial Development at Diosynth Biotechnology. Prior to Diosynth, he led programs on bioethanol, gene switches and natural products as Director of Business Development and Research at Syngenta and Novartis (USA and Switzerland). Dr. Chemla holds a PhD in Chemistry from the Louis Pasteur University and an MBA from the Duke University Fuqua School of Business.